Loading stock data…
MacroGenics, Inc. (MGNX)
$4.32-0.08 (-1.82%)
Market ClosedLast close Sep 8
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MacroGenics, Inc. in the Healthcare sector is trading at $4.32 with a market capitalization of $267M. Wall Street consensus targets $8.00 (4 analysts), implying a +85.2% move over the next 12 months. The stock is currently 15% below its 52-week high of $5.08, remaining 42.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +85.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.77M↓ | $41.23M↓ | $72.84M↑ | $22.24M↑ | $13.19M |
| Gross Profit | $11.24M↓ | $31.11M↓ | $61.25M↑ | $13.34M↑ | $7.79M |
| Operating Income | -$33.44M↓ | -$12.10M↓ | $18.64M↑ | -$36.76M↑ | -$42.62M |
| Net Income | -$36.77M↓ | -$14.15M↓ | $16.82M↑ | -$36.25M↑ | -$41.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$266.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-331.91%
Volume
Today's trading volume
419,046
Recent News
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)’s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies’ 2022 collaboration. That broader agreement spans three programs, including clinical-stage CD123 x CD3 […]
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of +32.50% and -25.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates
Sanara MedTech (SMTI) delivered earnings and revenue surprises of +150.00% and -4.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?